TY  - GEN
AU  - Miyahara,Koji
AU  - Nouso,Kazuhiro
AU  - Tomoda,Takeshi
AU  - Kobayashi,Sayo
AU  - Hagihara,Hiroaki
AU  - Kuwaki,Kenji
AU  - Toshimori,Junichi
AU  - Onishi,Hideki
AU  - Ikeda,Fusao
AU  - Miyake,Yasuhiro
AU  - Nakamura,Shinichiro
AU  - Shiraha,Hidenori
AU  - Takaki,Akinobu
AU  - Yamamoto,Kazuhide
TI  - Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma
SN  - 1440-1746
PY  - 2012///0213
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Angiogenic Proteins
KW  - blood
KW  - Antineoplastic Agents
KW  - adverse effects
KW  - Benzenesulfonates
KW  - Biomarkers, Tumor
KW  - Carcinoma, Hepatocellular
KW  - Cytokines
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Japan
KW  - Kaplan-Meier Estimate
KW  - Liver Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Niacinamide
KW  - analogs & derivatives
KW  - Phenylurea Compounds
KW  - Predictive Value of Tests
KW  - Proportional Hazards Models
KW  - Protein Kinase Inhibitors
KW  - Pyridines
KW  - Risk Assessment
KW  - Risk Factors
KW  - Sorafenib
KW  - Survival Rate
KW  - Time Factors
KW  - Treatment Outcome
KW  - Up-Regulation
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1111/j.1440-1746.2011.06887.x
ER  -